Stroke, Vol 20, 1089-1091, Copyright © 1989 by American Heart Association
M Yamamoto, A Tamura, T Kirino, M Hirakawa, M Shimizu and K Sano
We observed the effects of a new thyrotropin-releasing hormone analogue,
YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-
histidyl-L-prolinamide dihydrate) on behavioral changes in 26 rats
subjected to middle cerebral artery occlusion. The administration of 0.1
mg/kg i.p. YM-14673 was started 1 week after occlusion and was repeated
daily for 2 weeks. YM-14673 significantly accelerated the recovery of
neurologic deficits and ameliorated the disturbance of passive avoidance
learning. Thus, YM-14673 improved behavioral response in a model of chronic
focal cerebral ischemia. The availability of a chronic middle cerebral
artery occlusion model for the evaluation of drugs is also discussed.
ARTICLES
Effects of a new thyrotropin-releasing hormone analogue administered in rats 1 week after middle cerebral artery occlusion
Department of Pharmacology, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan.
This article has been cited by other articles:
![]() |
H. Yanamoto, I. Nagata, Y. Niitsu, Z. Zhang, J.-H. Xue, N. Sakai, H. Kikuchi, and C. Iadecola Prolonged Mild Hypothermia Therapy Protects the Brain Against Permanent Focal Ischemia Editorial Comment Stroke, January 1, 2001; 32(1): 232 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yanamoto, I. Nagata, I. Nakahara, N. Tohnai, Z. Zhang, H. Kikuchi, and C. Iadecola Combination of Intraischemic and Postischemic Hypothermia Provides Potent and Persistent Neuroprotection Against Temporary Focal Ischemia in Rats • Editorial Comment Stroke, December 1, 1999; 30(12): 2720 - 2726. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |